Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

A new FDA application for relacorilant shows promising survival benefits in treating platinum-resistant ovarian cancer, ...

PanTher Therapeutics today announced that the first patient has been treated with PTM-101 in a Phase 1b trial in pancreatic ductal adenocarcinoma.

We demonstrate this approach by taking doxorubicin- and paclitaxel-resistant breast cancer cells as model systems. We find that inhibiting the selected targets in the drug-resistant cells together ...

Purpose Intraperitoneal (IP) cisplatin and intravenous (IV) or IP paclitaxel constitute a standard therapy for optimally debulked ovarian cancer. Bevacizumab prolongs progression-free survival (PFS) ...